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Figure 2. COMP value in ACL, Normal and OA groups.
and ACL patients (p<0.01). There was no signiﬁcant difference in
CS846 levels between ACL patients and those who were healthy
(p=0.18). Likewise, COMP levels were signiﬁcantly higher in OA
patients vs. healthy and ACL patients (p<0.04). Again, there was
no signiﬁcant difference in COMP levels between ACL patients
and those who were healthy (p=0.95).
Conclusions: In this study, CS846 and COMP markers were
signiﬁcantly higher in knee OA patients than ACL patients and
healthy volunteers suggesting that OA patients are undergoing
more cartilage degeneration and attempt at cartilage repair than
the other groups. The lack of signiﬁcant differences between the
ACL and healthy groups may reﬂect the young age of the ACL
patients, the relatively short time since injury (average 3.4 yrs) or
perhaps the time dependent nature of attempted cartilage repair.
In addition, because these values are systemic and not localized
to the knee, lower average values may reﬂect overall generally
healthy cartilage which may mask higher levels at the site of
injury.
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Purpose: Disease-modifying anti-rheumatic drugs (DMARDs)
suppress inﬂammation, and retard cartilage degradation and
bone erosion in arthritis. The molecular mechanisms of action
of many traditional DMARDs are not known in detail. Their
effects on macrophages and synovial cells have been inves-
tigated but very little is known on their effects on cartilage
and inﬂammatory factors produced by affected chondrocytes.
Inducible prostaglandin synthase (cyclooxygenase-2, COX-2) is
expressed in rheumatoid and osteoarthritic cartilage and pro-
duces high amounts of proinﬂammatory prostanoids in the joint.
Mitogen-activated protein kinases (MAPKs) are a family of ser-
ine/threonine kinases that mediate inﬂammatory and other extra-
cellular signals to intracellular target proteins, e.g. transcription
factors that regulate gene expression. In the present study, we
investigated the effects of different DMARDs on interleukin-1β
(IL-1β) -induced COX-2 expression and further, aurothiomalate’s
effects and mechanisms of action in chondrocyte cultures and in
human cartilage in more detail.
Methods: Cartilage tissue was obtained from the leftover pieces
of total knee replacement surgery from patients with OA. Im-
mortalized H4 murine chondrocytes* were used in cell culture
experiments.
Results: In the present study, we investigated the effects of tra-
ditional DMARDs on COX-2 expression in chondrocytes. Unlike
the other tested compounds (cyclosporin A, hydroxychloroquine,
leﬂunomide, its active metabolite A771726, methotrexate and
sulfasalazine), aurothiomalate was found to be effective at clini-
cally relevant drug concentrations. Aurothiomalate inhibited IL-1β
-induced prostaglandin E2(PGE2) production in chondrocytes
and in human cartilage. Aurothiomalate inhibited also COX-2
expression by destabilizing its mRNA as did p38 MAPK inhibitor
SB203580. Interestingly, aurothiomalate inhibited the phospho-
rylation of JNK and p38 MAPKs, which may well explain its
inhibitory effect on COX-2 expression and PGE2 production in
chondrocytes.
Conclusions: The results provide a novel mechanism for the
anti-inﬂammatory action of aurothiomalate through reduced p38
and JNK MAPK activation and COX-2 expression, and stress
chondrocytes and their products as important targets in drug
development for arthritis.
*Murine H4 chondrocyte cell line was kindly provided by Peter
van der Kraan from Laboratory of Experimental Rheumatology,
University Medical Center Nijmegen, The Netherlands.
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Purpose and aim: Nitric oxide (NO) is an important mediator
of inﬂammation and joint destruction in rheumatoid arthritis (RA)
and osteoarthritis (OA). Oxygen reactive species induced by
NO can transform tyrosine residues of joint tissue proteins into
nitrosylated modiﬁed forms. An ELISA recognizing speciﬁcally
degradation fragments of the nitrosylated-modiﬁed telopeptide
(IIINys) of type III collagen -an abundant protein of synovial
tissue- has been developed and increased circulating IIINys
levels were found in patients with active RA. However, the tissue
origin of IIINys was not determined and no data in OA has yet
been reported. The aim of this study was to investigate whether
type III collagen nitrosylation can be detected in the synovial
tissue of patients with OA and RA and be reﬂected by changes
in synovial ﬂuid and circulating IIINys levels.
Methods: Synovial tissue of the knee joint was obtained from
patients with knee OA (n= 4), patients with RA (n=5) and non-
arthritic controls (n = 2) during joint replacement. Levels of IIINys
were measured by ELISA in knee joint ﬂuid and paired plasma
samples from 11 patients with knee OA and 11 patients with
active RA. We also measured circulating IIINys levels in 89
patients with painful knee OA (79% women; mean age 63.0;
mean disease duration 6.1 years, radiological Kellgren-Lawrence
score II or III), 55 patients with active RA (65% female, mean
age: 55 years, mean disease duration 14 years) and 83 healthy
women and men (20 to 60 yrs of age)
